Genitourinary Cancer News

The National Academy of Medicine announced the election of 90 regular members and 10 international members.

Pembrolizumab significantly improved DFS compared with observation for the adjuvant treatment of patients with localized muscle-invasive urothelial carcinoma and locally advanced urothelial carcinoma, according to the agent’s manufacturer.

Michael J. Zelefsky, MD, has been appointed director of brachytherapy for NYU Langone’s Perlmutter Cancer Center.

Stereotactic ablative body radiotherapy conferred 100% disease control and cancer-specific survival over a 3-year follow-up period among older adults with inoperable kidney cancer, results from a phase 2 study showed.

ASCO released a research statement outlining new recommendations regarding the appropriate assessment of ovarian toxicity in cancer clinical trials.

The FDA announced several regulatory actions.

Nearly seven in 10 premature cancer-related deaths among women could have been avoided through primary prevention, early detection or suitable access to cancer care, according to a report.

The combination of pembrolizumab plus enfortumab vedotin significantly extended OS and PFS as first-line treatment for adults with locally advanced or metastatic urothelial carcinoma, according to the manufacturers of both agents.

Relative risk for venous thromboembolism appeared high among patients with COVID-19 and cancer who received specific cancer treatments, according to study results published in JAMA Oncology.

Results from the American Association for Cancer Research’s annual Cancer Progress Report revealed that the age-adjusted overall cancer death rate in the U.S. fell by 33% between 1991 and 2020.